Core Insights - Telix Pharmaceuticals is launching two additional products, Pixclara for glioblastoma and Zircaix for renal cancer, pending regulatory outcomes [1] - The company reported a full-year revenue of $804 million, reflecting a 56% increase, and is guiding for 2026 revenue of $950 million to $970 million, indicating over 20% growth [6][11] - Telix emphasizes its vertically integrated radiopharmaceutical platform, having invested over $500 million in manufacturing and supply chain improvements [2][6] Financial Performance - Full-year revenue reached $804 million, up 56%, marking the third consecutive year of double-digit growth [8] - Adjusted EBITDA was $39.5 million, with a gross margin of 53% [9] - The precision medicine segment saw a 22% year-over-year revenue increase, totaling $622 million [15] Product Pipeline and Strategy - Key pipeline priorities include resubmissions for Pixclara and Zircaix, with potential approvals targeted for 2026 [5][7] - The company is focusing on a dual-product strategy with its PSMA agents, which provides competitive advantages in customer choice and reimbursement dynamics [17] - Telix plans to invest $200 million to $240 million in R&D for 2026, primarily directed towards therapeutics development [12] Global Expansion and Regulatory Efforts - Illuccix is available in 17 countries, with ongoing efforts for market access in key European markets [18] - The company has submitted an NDA in China and is progressing with a Phase III study in Japan [19] - Regulatory submissions for Pixclara and Zircaix are in progress, with the company confident in meeting FDA requirements for resubmission [20][21]

Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to $804 million, marking its third consecutive year of double-digit revenue growth [17][19] - EBITDA improved by 25% to $216 million, driven by strong demand for Illuccix and the launch of Gleolan [19][23] - The gross margin remained stable at 53%, with a significant portion of gross margin generated from the precision medicine business [22][23] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional $113 million [19][23] - The precision medicine business generated approximately $400 million in gross margin, with 94% of the gross margin coming from this segment [20][23] - Investments in product development totaled $157 million, focusing on late-stage pipeline projects [22] Market Data and Key Metrics Changes - The precision medicine portfolio delivered $622 million in revenue, with sequential growth every quarter, even during challenging market conditions [30] - The company is expanding its market presence, with Illuccix now available in 17 countries and marketing authorizations in over 24 markets [35] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investments ranging from $200 million to $240 million in 2026 [26] - A dual product strategy for Illuccix and Gleolan is in place to manage economic needs and reimbursement preferences effectively [58][60] - The company is focused on expanding its product offerings, indications, and geographical reach, particularly in key markets like the U.K., Germany, and China [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving approximately 20% revenue growth in 2026, with guidance set at $950 million to $970 million [28][29] - The company is committed to reinvesting earnings into R&D and commercial growth rather than optimizing near-term earnings per share [68] - Management highlighted the importance of clinical credibility and operational reliability in sustaining market leadership [32][33] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials expected to generate significant data this year [47] - The ProstACT Global study is progressing well, with recruitment for part two ramping up [48][49] Q&A Session Questions and Answers Question: When might we see data for 591, the safety data? - The company is completing clinical case report forms and will disclose the data simultaneously with the FDA submission, with no delays expected from the FDA side [54][56] Question: Can you elaborate on the early performance of the two-product strategy for Illuccix and Gleolan? - The two-product strategy allows the company to manage economic needs and reimbursement preferences effectively, adapting to changes in the reimbursement environment [58][60] Question: Will the company reinvest earnings to achieve close to zero NPAT for F-26, F-27, and F-28? - The company will reinvest the majority of earnings back into R&D and commercial growth, with no profit objective for the next two years [68] Question: How much growth in precision medicine revenue is coming from markets outside of the U.S.? - Currently, 95% of revenue is U.S.-based, but the company expects this mix to change as it expands into other markets like Japan [74]

Core Insights - Medexus Pharmaceuticals reported its operating and financial results for the third fiscal quarter ended December 31, 2025, highlighting the positive market response to GRAFAPEX and its expected contribution to future revenues [1][2][7]. Financial Performance - For fiscal Q3 2026, Medexus achieved net revenue of $25.3 million, a decrease of 15.7% year-over-year, primarily due to reduced sales of Rupall and the termination of the Gleolan license agreement [6]. - Adjusted EBITDA for the same period was $4.5 million, reflecting a decrease of 22.4% compared to the prior year, attributed to generic competition and the Gleolan agreement termination [6]. - Operating income was reported at $1.7 million, down 55.3% year-over-year, marking the third consecutive quarter of operating income growth since GRAFAPEX's launch [6]. GRAFAPEX Performance - GRAFAPEX generated product-level net revenue of $2.0 million and $8.2 million for the three- and nine-month periods ended December 31, 2025, with expectations of exceeding $100 million in annual revenue within five years [2][8]. - There was a 30% sequential increase in underlying patient demand for GRAFAPEX in fiscal Q3 2026 compared to fiscal Q2 2026, with a notable 56% increase in demand from adult hospitals [3][8]. - As of December 31, 2025, 32% of US transplant centers had ordered GRAFAPEX, with 77% of those institutions placing repeat orders [3][9]. Operational Highlights - The company has invested $8.5 million in GRAFAPEX's launch, which has significantly impacted its market performance [3][5]. - Medexus anticipates that GRAFAPEX will contribute positively to quarterly operating cash flows starting in fiscal Q4 2026, with expected product-level Adjusted Gross Margin of approximately 80% [8][9]. Corporate Developments - Medexus entered into a new credit agreement with the National Bank of Canada, providing a $21.0 million term loan facility and a $5.0 million revolving loan facility, enhancing its financial stability [12]. - The company has repurchased 191,900 common shares under its normal course issuer bid, reflecting its commitment to returning value to shareholders [12].